AKT1 and prostate cancer: In order to study the effects of endothelial Akt1 suppression on prostate cancer cell metastasis in vivo, we utilised a tamoxifen-inducible, endothelial-specific Akt1-deficient mouse model (Fig. 7a) and murine RM1 metastatic prostate cancer cell line of C57/BL6 origin.